Based on the results of H1 2014, the Representative Office of Farmak in Uzbekistan is ranked among Top 10 largest pharmaceutical manufacturers in the market of the Republic of Uzbekistan.
According to Drug Audit, an analytical and information pharmaceutical database, provided by Yevro Farmis, the Representative Office of Farmak in the Republic of Uzbekistan was ranked 9th, based on the results of H1 2014, with a market share of 2.15% in US dollars.
Farida Akhmetova, Director, Representative Office of Farmak in the Republic of Uzbekistan, says, “Representative Office of Farmak in Uzbekistan was opened 10 years ago, in 2004. The Representative Office was then ranked 24th in the pharmaceutical market with the sales share of 1.16% in money terms. However, even then we set on a target to become ranked among Top-10 pharmaceutical companies in Uzbekistan.
Reaching that target was not easy. Firstly, the market has rather intensive competition (according to Drug Audit, 424 pharmaceutical manufacturers were present in the Uzbekistan pharmaceutical market in Q2 2014). Secondly, activities of our top competitors kept us busy every single moment. However, smooth and professional work of our team allowed the Representative Office of Farmak to climb to No. 9 ranking with 2.15% market share in monetary terms in Q2 2014”.
Nearly 60 Farmak medicinal products in various doses and dosage forms are approved for the today's Uzbekistan pharmaceutical market. The product portfolio of Representative Office of Farmak in Uzbekistan covers diverse therapeutic categories: endocrinology, neurology, cardiology, rheumatology, gastroenterology, ophthalmology products, and products for treatment of cold-related diseases.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...